Large state-wide variation (11.1-fold) in number of clozapine prescriptions per thousand Medicare Part D enrollees in 2015 ^a indicates ≥1.50 SD (20.2) from the mean (36.... حسب Luke R. Cavanah (19022435)

الموضوعات:

Large state-wide variation (8.6-fold) in number of clozapine prescriptions per thousand Medicare Part D enrollees in 2017 ^a indicates ≥1.50 SD (18.0) from the mean (33.1... حسب Luke R. Cavanah (19022435)

الموضوعات:

Long-term anti-nucleocapsid response by baseline patient characteristics. حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Baseline patient characteristics across neutralizing monoclonal antibody trials. حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Large state-wide variation (8.6-fold) in number of clozapine prescriptions per thousand Medicare Part D enrollees in 2018 ^a indicates ≥1.50 SD (17.9) from the mean (32.9... حسب Luke R. Cavanah (19022435)

الموضوعات:

Large state-wide variation (8.5-fold) in number of clozapine prescriptions per thousand Medicare Part D enrollees in 2019 ^a indicates ≥1.50 SD (16.8) from the mean (31.0... حسب Luke R. Cavanah (19022435)

الموضوعات:

Large state-wide variation (10.2-fold) in number of clozapine prescriptions per thousand Medicare Part D enrollees in 2016 ^a indicates ≥1.50 SD (19.2) from the mean (34.... حسب Luke R. Cavanah (19022435)

الموضوعات:

Large state-wide variation (8.6-fold) in number of clozapine prescriptions per thousand Medicare Part D enrollees in 2020 ^a indicates ≥1.50 SD (16.0) from the mean (29.9... حسب Luke R. Cavanah (19022435)

الموضوعات:

Innovation and night light in large and small cities. حسب Saul Estrin (8629173)

Geographical distribution of large cities and small cities. حسب Saul Estrin (8629173)

"…The Figure reveals two patterns: 1) the maximum level of innovation is higher in large cities (2.53) than in small cities (2.02); 2) among large cities in <b>a</b>, innovation levels in general decrease with nightlight density. …"

GI-1d-a: Comparison of estimates of people for dataset A (left bar) and B (right bar) per region. The largest discrepancies occur in areas of NE, SE and SW Germany and adjacent reg... حسب Isabell Schmidt (6331013)

الموضوعات:

Image 1_Exploration of the diagnostic and prognostic roles of decreased autoantibodies in lung cancer.tif حسب Ying Ye (72583)

"…A follow-up process for 13 patients diagnosed with early-stage lung cancer revealed that 10 of the 15 decreased autoantibodies would recover to a higher level after the tumor was resected. …"

Baseline patient characteristics. حسب Oscar F. C. van den Bosch (22184246)

"…This study was conducted as part of a randomized controlled trial originally designed to assess the effects of s-ketamine conditioning on pain sensitivity in patients with fibromyalgia syndrome. Participants were randomly assigned to receive an infusion of either s-ketamine (0.3 mg kg^-1 h^-1), midazolam (0.05 mg kg^-1 h^-1), or saline in a blinded fashion. …"

The capture efficiency of BioMagnetic solutions FerroSelect in PBS/1% BSA and whole blood showed a decrease in capture efficiency when moving to whole blood. حسب Peng Liu (120506)

Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for nMAbs, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis). حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for neutralizing monoclonal antibodies, among patients alive and with day 90 antibody and antigen measu... حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Antibody and antigen responses to Lufotrelvir vs placebo day 1–90. حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Antibody and antigen responses to Ensovibep vs placebo day 1–90. حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab. حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab. حسب Elizabeth S. Munroe (21568166)

الموضوعات: